FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309164570> ?p ?o ?g. }

• W4309164570 endingPage "825" @default.
• W4309164570 startingPage "816" @default.
• W4309164570 abstract "PURPOSE To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)–low gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS Patients with locally advanced or metastatic HER2-low (cohort 1, immunohistochemistry 2+/in situ hybridization–negative; cohort 2, immunohistochemistry 1+) gastric/GEJ adenocarcinoma treated with at least two prior regimens, including fluoropyrimidine and platinum, but anti-HER2 therapy naive, received T-DXd 6.4 mg/kg intravenously once every 3 weeks. The primary end point was confirmed objective response rate by independent central review. RESULTS Among 21 patients enrolled in cohort 1 and 24 enrolled in cohort 2, 19 and 21 patients, respectively, had central HER2 confirmation, received T-DXd, and had measurable tumors at baseline. The confirmed objective response rate was 26.3% (95% CI, 9.1 to 51.2) from five partial responses in cohort 1 and 9.5% (95% CI, 1.2 to 30.4) from two partial responses in cohort 2. Thirteen patients (68.4%) in cohort 1 and 12 (60.0%) in cohort 2 experienced reduced tumor size. The median overall survival was 7.8 months (95% CI, 4.7 to nonevaluable) in cohort 1 and 8.5 months (95% CI, 4.3 to 10.9) in cohort 2; the median progression-free survival was 4.4 months (95% CI, 2.7 to 7.1) and 2.8 months (95% CI, 1.5 to 4.3), respectively. The most common grade ≥ 3 treatment-emergent adverse events in cohorts 1 and 2 were anemia (30.0% and 29.2%), decreased neutrophil count (25.0% and 29.2%), and decreased appetite (20.0% and 20.8%). Drug-related interstitial lung disease/pneumonitis occurred in one patient in each cohort (grade 1 or 2). No drug-related deaths occurred. CONCLUSION This study provides preliminary evidence that T-DXd has clinical activity in patients with heavily pretreated HER2-low gastric/GEJ adenocarcinoma." @default.
• W4309164570 created "2022-11-24" @default.
• W4309164570 creator A5007258796 @default.
• W4309164570 creator A5009457371 @default.
• W4309164570 creator A5015799240 @default.
• W4309164570 creator A5019406140 @default.
• W4309164570 creator A5021699640 @default.
• W4309164570 creator A5022874036 @default.
• W4309164570 creator A5035238172 @default.
• W4309164570 creator A5040676201 @default.
• W4309164570 creator A5045750261 @default.
• W4309164570 creator A5050684671 @default.
• W4309164570 creator A5055657000 @default.
• W4309164570 creator A5056231306 @default.
• W4309164570 creator A5067881155 @default.
• W4309164570 creator A5070941567 @default.
• W4309164570 creator A5077943312 @default.
• W4309164570 creator A5084847095 @default.
• W4309164570 creator A5085952795 @default.
• W4309164570 creator A5091701897 @default.
• W4309164570 date "2023-02-01" @default.
• W4309164570 modified "2023-10-05" @default.
• W4309164570 title "Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial" @default.
• W4309164570 cites W2078454159 @default.
• W4309164570 cites W2100439220 @default.
• W4309164570 cites W2136197678 @default.
• W4309164570 cites W2314772071 @default.
• W4309164570 cites W2387397851 @default.
• W4309164570 cites W2507354993 @default.
• W4309164570 cites W2760931533 @default.
• W4309164570 cites W2897154408 @default.
• W4309164570 cites W2917113139 @default.
• W4309164570 cites W2943729639 @default.
• W4309164570 cites W2946663880 @default.
• W4309164570 cites W2953684910 @default.
• W4309164570 cites W3005585857 @default.
• W4309164570 cites W3013862212 @default.
• W4309164570 cites W3031843634 @default.
• W4309164570 cites W3042830787 @default.
• W4309164570 cites W3135570753 @default.
• W4309164570 cites W3147820834 @default.
• W4309164570 cites W3172138759 @default.
• W4309164570 cites W4242151806 @default.
• W4309164570 cites W4281640394 @default.
• W4309164570 doi "https://doi.org/10.1200/jco.22.00575" @default.
• W4309164570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36379002" @default.
• W4309164570 hasPublicationYear "2023" @default.
• W4309164570 type Work @default.
• W4309164570 citedByCount "13" @default.
• W4309164570 countsByYear W43091645702023 @default.
• W4309164570 crossrefType "journal-article" @default.
• W4309164570 hasAuthorship W4309164570A5007258796 @default.
• W4309164570 hasAuthorship W4309164570A5009457371 @default.
• W4309164570 hasAuthorship W4309164570A5015799240 @default.
• W4309164570 hasAuthorship W4309164570A5019406140 @default.
• W4309164570 hasAuthorship W4309164570A5021699640 @default.
• W4309164570 hasAuthorship W4309164570A5022874036 @default.
• W4309164570 hasAuthorship W4309164570A5035238172 @default.
• W4309164570 hasAuthorship W4309164570A5040676201 @default.
• W4309164570 hasAuthorship W4309164570A5045750261 @default.
• W4309164570 hasAuthorship W4309164570A5050684671 @default.
• W4309164570 hasAuthorship W4309164570A5055657000 @default.
• W4309164570 hasAuthorship W4309164570A5056231306 @default.
• W4309164570 hasAuthorship W4309164570A5067881155 @default.
• W4309164570 hasAuthorship W4309164570A5070941567 @default.
• W4309164570 hasAuthorship W4309164570A5077943312 @default.
• W4309164570 hasAuthorship W4309164570A5084847095 @default.
• W4309164570 hasAuthorship W4309164570A5085952795 @default.
• W4309164570 hasAuthorship W4309164570A5091701897 @default.
• W4309164570 hasBestOaLocation W43091645701 @default.
• W4309164570 hasConcept C121608353 @default.
• W4309164570 hasConcept C126322002 @default.
• W4309164570 hasConcept C143998085 @default.
• W4309164570 hasConcept C2779786085 @default.
• W4309164570 hasConcept C530470458 @default.
• W4309164570 hasConcept C71924100 @default.
• W4309164570 hasConcept C72563966 @default.
• W4309164570 hasConcept C90924648 @default.
• W4309164570 hasConceptScore W4309164570C121608353 @default.
• W4309164570 hasConceptScore W4309164570C126322002 @default.
• W4309164570 hasConceptScore W4309164570C143998085 @default.
• W4309164570 hasConceptScore W4309164570C2779786085 @default.
• W4309164570 hasConceptScore W4309164570C530470458 @default.
• W4309164570 hasConceptScore W4309164570C71924100 @default.
• W4309164570 hasConceptScore W4309164570C72563966 @default.
• W4309164570 hasConceptScore W4309164570C90924648 @default.
• W4309164570 hasIssue "4" @default.
• W4309164570 hasLocation W43091645701 @default.
• W4309164570 hasLocation W43091645702 @default.
• W4309164570 hasLocation W43091645703 @default.
• W4309164570 hasOpenAccess W4309164570 @default.
• W4309164570 hasPrimaryLocation W43091645701 @default.
• W4309164570 hasRelatedWork W2152621900 @default.
• W4309164570 hasRelatedWork W2164097569 @default.
• W4309164570 hasRelatedWork W2300577200 @default.
• W4309164570 hasRelatedWork W2555279718 @default.
• W4309164570 hasRelatedWork W2603773853 @default.
• W4309164570 hasRelatedWork W2984545096 @default.

• next